secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001493152-26-021306
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock
--------------------------------------------------------------------------------

- Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).
- Shares convertible at $1.50/common, but conversion requires stockholder approval; no conversion allowed before approval.
- Oncotelic retains perpetual, exclusive, royalty-free license to use the patents except for Biodefense and Alzheimer's fields.
- Oncotelic agreed to issue 10% of fully diluted shares to Autotelic upon uplisting in exchange for assets including peptide Y, PTH, insulin formulations.
- All transactions completed May 1, 2026; no cash exchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/0001493152-26-021306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer